Effectiveness of switch therapy from tyrosine kinase inhibitors to immune checkpoint inhibitors: the need for biomarkers to establish treatment strategies in patients with metastatic renal cell carcinoma

Transl Androl Urol. 2024 Apr 30;13(4):631-634. doi: 10.21037/tau-23-647. Epub 2024 Apr 12.

¹ Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
² Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.

No abstract available

Keywords: Nivolumab; immune checkpoint inhibitor (ICI); renal cell carcinoma (RCC); tyrosine kinase inhibitor (TKI).

Publication types